Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000432534

Medchemexpress LLC Flumazenil | 78755-81-4 | >99.9% | C15H14FN3O3 | 5 MG
SDP

Catalog No. 5000432534
Encompass_Preferred

Flumazenil is a competitive GABAA receptor antagonist, primarily used in the treatment of benzodiazepine overdoses. It works by interacting at the central benzodiazepine receptor to antagonize or reverse the behavioral, neurologic, and electrophysiologic effects caused by benzodiazepine agonists and inverse agonists.

  • Functions as a competitive GABAA receptor antagonist
  • Clinically used to treat benzodiazepine overdoses
  • Reverses behavioral, neurologic, and electrophysiologic effects of benzodiazepine agonists
  • May offer benefit in hepatic encephalopathy, pending further clinical trials
  • Induces a strong anxiolytic effect in certain mice models
  • Antagonizes anticonvulsant and adverse effects of diazepam
  • Blocks changes associated with withdrawal from chronic ethanol treatment

Catalog No. 50-004-32534 Supplier Medchemexpress LLC Supplier No. HYB00095MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Flumazenil is a competitive GABAA receptor antagonist, primarily used in the treatment of benzodiazepine overdoses. It works by interacting at the central benzodiazepine receptor to antagonize or reverse the behavioral, neurologic, and electrophysiologic effects caused by benzodiazepine agonists and inverse agonists.

  • Functions as a competitive GABAA receptor antagonist
  • Clinically used to treat benzodiazepine overdoses
  • Reverses behavioral, neurologic, and electrophysiologic effects of benzodiazepine agonists
  • May offer benefit in hepatic encephalopathy, pending further clinical trials
  • Induces a strong anxiolytic effect in certain mice models
  • Antagonizes anticonvulsant and adverse effects of diazepam
  • Blocks changes associated with withdrawal from chronic ethanol treatment

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.